Literature DB >> 18284355

US Civilian Smallpox Preparedness and Response Program, 2003.

Raymond A Strikas1, Linda J Neff, Lisa Rotz, Joanne Cono, Donna Knutson, Joseph Henderson, Walter A Orenstein.   

Abstract

Variola virus, the cause of smallpox disease, has been deemed a possible bioterrorism agent. Since November 2001, federal, state, and local public health partners implemented activities to prepare for a possible smallpox outbreak. The Centers for Disease Control and Prevention (CDC) produced and delivered training and educational materials for smallpox preparedness in many formats, developed detailed smallpox vaccine information statements about vaccine contraindications and vaccination site care, and established mechanisms to monitor and respond to adverse events after smallpox vaccination. The last included enhancements to the Vaccine Adverse Event Reporting System, a pregnancy registry for inadvertently vaccinated pregnant women, and a Clinician Telephone Information Line to collect reports about adverse events. The civilian responder vaccination program was conducted with rigorous safety procedures, and few historically recognized adverse events were observed. However, myocarditis and/or pericarditis was newly recognized as an adverse event caused by the New York City Board of Health vaccinia vaccine strain. This smallpox preparedness program put into place a number of measures to advance the United States' readiness for a smallpox outbreak that have assisted in preparedness for other threats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284355     DOI: 10.1086/524751

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

Review 2.  Assessing risk in chronic kidney disease: a methodological review.

Authors:  Morgan E Grams; Josef Coresh
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

3.  Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.

Authors:  Richard Kennedy; V Shane Pankratz; Eric Swanson; David Watson; Hana Golding; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2009-06-17

4.  Secondary and tertiary transmission of vaccinia virus from US military service member.

Authors:  Gregory E Young; Christina M Hidalgo; Ann Sullivan-Frohm; Cynthia Schult; Stephen Davis; Cassandra Kelly-Cirino; Christina Egan; Kimberly Wilkins; Ginny L Emerson; Kimberly Noyes; Debra Blog
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

Review 5.  The strategic use of novel smallpox vaccines in the post-eradication world.

Authors:  Joseph W Golden; Jay W Hooper
Journal:  Expert Rev Vaccines       Date:  2011-07       Impact factor: 5.683

6.  How are healthcare provider systems preparing for health emergency situations?

Authors:  Timothy DeVita; David Brett-Major; Rebecca Katz
Journal:  World Med Health Policy       Date:  2021-05-11

Review 7.  An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.

Authors:  Andrew T Russo; Douglas W Grosenbach; Jarasvech Chinsangaram; Kady M Honeychurch; Paul G Long; Candace Lovejoy; Biswajit Maiti; Ingrid Meara; Dennis E Hruby
Journal:  Expert Rev Anti Infect Ther       Date:  2020-09-15       Impact factor: 5.854

8.  Identification of protective T-cell antigens for smallpox vaccines.

Authors:  Jun Ando; Minhtran C Ngo; Miki Ando; Ann Leen; Cliona M Rooney
Journal:  Cytotherapy       Date:  2020-05-08       Impact factor: 6.196

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.